Study guide
23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient
Key Takeaways Explain This Topic AI
Current ASRA and addiction medicine consensus is to continue buprenorphine perioperatively and add titrated full agonists rather than stopping it 72 hours before surgery.
Maintenance methadone dosed once daily provides no meaningful acute analgesia because its analgesic duration is only 6 to 8 hours, so additional short-acting opioid is always required.
Oral naltrexone must be stopped at least 72 hours before elective surgery and extended-release injectable naltrexone requires at least 30 days, after which the patient is opioid-sensitive from receptor upregulation.
Opioid-tolerant patients need 30 to 100 percent more opioid than opioid-naive patients, and agonist-antagonists such as nalbuphine and butorphanol precipitate withdrawal and must be avoided.
When converting between opioids the calculated equianalgesic dose is reduced by 25 to 50 percent for incomplete cross-tolerance, using morphine 10 mg IV equal to 30 mg orally and hydromorphone 1.5 mg IV.
Last updated: August 2026
Why This Topic Matters on the NCE
Two separate parts of the content outline converge here: Domain III.L.2.b, chronic pain management , and Domain IV.B.5, the substance use disorder population including medication-assisted therapy, pharmacologic interactions, pain management , and management of complications. The opioid-tolerant surgical patient is the single most common place these two domains meet, and getting it wrong produces either uncontrolled agony or a respiratory arrest.
1. Non-Opioid Foundations of Chronic Pain Management
Class Agents and dosing Best evidence for Key cautions
Alpha-2-delta ligands Gabapentin 300 to 1200 mg; pregabalin 75 to 150 mg Neuropathic pain; preoperative dose reduces opioid use Renally cleared — reduce in renal impairment ; sedation and respiratory depression when combined with opioids, especially in the elderly and in obstructive sleep apnea
Tricyclic antidepressants Amitriptyline, nortriptyline Neuropathic pain, especially with insomnia Anticholinergic effects, QT prolongation, orthostasis
SNRIs Duloxetine 30 to 60 mg Diabetic neuropathy, fibromyalgia, osteoarthritis Enhances descending noradrenergic inhibition; serotonin syndrome risk
NSAIDs / acetaminophen Ketorolac, celecoxib, acetaminophen 1000 mg Nociceptive and inflammatory pain Renal function, bleeding, bone healing debate
- Topical agents Lidocaine 5% patch, capsaicin Localized neuropathic pain Minimal systemic absorption
- Infusion adjuvants used perioperatively
Ketamine : a bolus of 0.25 to 0.5 mg/kg followed by an infusion of roughly 0.1 to 0.3 mg/kg/h reliably reduces opioid consumption and is most valuable in the opioid-tolerant patient.
Lidocaine : 1 to 2 mg/kg bolus then 1 to 2 mg/kg/h, best supported in open and laparoscopic abdominal surgery within enhanced recovery pathways. Do not combine with a large-volume regional block without accounting for total local anesthetic dose.
Dexmedetomidine : 0.2 to 0.7 mcg/kg/h, opioid sparing without respiratory depression.
Methadone : a single intraoperative dose of roughly 0.1 to 0.3 mg/kg provides prolonged analgesia through combined mu agonism and NMDA antagonism. Watch for QT prolongation and remember its long and variable half-life of 15 to 60 hours.
Regional anesthesia and analgesia is first-line for the opioid-tolerant patient whenever the surgery permits it.
- 2. The Opioid-Tolerant Surgical Patient
- Core principle
Continue the baseline opioid requirement and treat the acute surgical pain on top of it. The single most common and most dangerous error is stopping the home opioid at admission, which produces withdrawal and leaves the acute pain untreated.
Verify the home regimen with the prescriber, the pharmacy, or the prescription drug monitoring program.
Expect acute opioid requirements 30 to 100 percent above those of an opioid-naive patient for the same operation.
Do not rely on as-needed dosing alone. Use scheduled baseline dosing plus patient-controlled analgesia with a higher demand dose, and consider a background infusion in the genuinely tolerant patient.
Avoid agonist-antagonists and partial agonists — nalbuphine, butorphanol, and buprenorphine given acutely to a patient on a full agonist will displace it and precipitate withdrawal and severe pain.
Equianalgesic conversion
- Opioid Parenteral Oral
- Morphine 10 mg 30 mg
- Hydromorphone 1.5 mg 7.5 mg
- Fentanyl 100 mcg —
- Oxycodone — 20 mg
When converting between opioids, reduce the calculated dose by 25 to 50 percent to account for incomplete cross-tolerance, then titrate up. Methadone conversion is nonlinear and dose dependent and should not be estimated with a simple ratio.
- 3. Medication-Assisted Therapy: The Three Drugs
- Buprenorphine
A partial mu agonist with very high receptor affinity and slow dissociation. It has a ceiling on respiratory depression but not on analgesia , and its high affinity means full agonists cannot easily displace it.
Historic practice was to stop buprenorphine 72 hours before surgery. Current consensus guidance from ASRA, the American Society of Addiction Medicine, and allied societies recommends continuing buprenorphine perioperatively for most patients, because discontinuation destabilizes recovery, risks relapse and overdose death, and is not required for adequate analgesia.
Continue the home dose, or divide it into two or three daily doses to exploit its analgesic duration.
Add titrated full agonists , regional anesthesia, ketamine, and non-opioid multimodal therapy on top. Higher full-agonist doses may be needed to compete for receptors, so monitor accordingly.
Consider dose reduction only for very high doses in consultation with the prescriber, and never abruptly.
Methadone (for opioid use disorder)
A full mu agonist with NMDA antagonism and a long, variable half-life.
Continue the maintenance dose and verify it directly with the opioid treatment program — federal regulation governs these programs and the dose must be confirmed, not assumed.
Critically, the once-daily maintenance dose provides no meaningful acute analgesia , because the analgesic duration is only 6 to 8 hours while the dosing interval is 24 hours. Additional short-acting opioid is required for surgical pain.
QT prolongation and torsades risk; check an ECG when combining with other QT-prolonging drugs.
Naltrexone
A full mu antagonist — the mirror-image problem. Opioids will not work.
Oral naltrexone : discontinue at least 72 hours before elective surgery.
Extended-release injectable naltrexone (monthly depot): schedule elective surgery at least 30 days after the last injection.
After any period off naltrexone the patient is opioid-naive and highly sensitive — receptor upregulation means standard doses can cause respiratory arrest.
For emergency surgery in a naltrexone-blocked patient, plan a non-opioid strategy : regional anesthesia, ketamine, dexmedetomidine, lidocaine infusion, acetaminophen and NSAIDs, and high-dependency monitoring if high-dose opioid is used to overcome the blockade.
4. Practical Perioperative Algorithm
Identify and verify all chronic opioid, buprenorphine, methadone, and naltrexone therapy preoperatively.
Continue baseline therapy; never stop it at the door.
Choose a regional technique whenever the surgery allows.
Load multimodal non-opioids: acetaminophen, an NSAID if permitted, a gabapentinoid where appropriate, dexamethasone.
Add ketamine, lidocaine, or dexmedetomidine infusions intraoperatively.
Anticipate substantially higher opioid requirements and use scheduled plus patient-controlled dosing.
Monitor for sedation and respiratory depression with capnography in the high-risk patient.
Communicate a clear discharge plan with the prescriber and avoid discharging on an escalated long-term regimen.
Exam Traps
Do not stop buprenorphine. Current guidance is to continue it and add full agonists.
Maintenance methadone is not analgesia. Additional short-acting opioid is required.
Extended-release naltrexone needs 30 days , oral naltrexone 72 hours.
Never give nalbuphine or butorphanol to a patient on chronic full agonists — precipitated withdrawal.
Reduce by 25 to 50 percent when converting between opioids for incomplete cross-tolerance.